SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Herceptin® in HER2 1 /2 Breast Cancer Patients

SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Herceptin® in HER2 1 /2 Breast Cancer Patients

Commentaires

Articles les plus consultés